ArticleThe Pan African medical journal2025
Mpox-HIV co-infection in the mpox treatment centre in Kokolo Health District, Kinshasa, Democratic Republic of the Congo, November 2024 to March 2025.
Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mpox-HIV co-infection in a low-incidence setting: epidemiological insights from Qinghai, China.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: mpox infection is an emerging zoonosis with a significant impact on public health. HIV is an infection that often causes a decline in the immunity of patients. In the event of mpox-HIV co-infection, patients see their immunity drop further. In addition to the classic clinical manifestations, patients with mpox-HIV co-infection can develop severe forms of the disease. The objective of this study is to determine the prevalence of cases of mpox-HIV co-infection among people living with mpox in the mpox Treatment Centre (MpoxTC) in Kokolo Health District. Methods: this is a descriptive cross-sectional study conducted in the MpoxTC of the Kokolo Health District, from November 26, 2024, to March 11, 2025. Exhaustive sampling was used with 118 mpox-confirmed patients. Excel 2019 was used for the data entry, and Epi Info 7.2.6.0 was used for statistical analyses, including Chi-square and Student t tests to explore associations between variables. Results: the study revealed a prevalence of 9.32% mpox-HIV coinfection 11/118, with all infections occurring through sexual contact. In total, mpox-VIH co-infected patients were distributed in 7 health areas (HAs), of which 71.43% (5/7) were urban HAs and 28.57% (2/7) were peri-urban HAs. A prolonged duration of hospitalization (>10 days) concerned 55.09% or 65/118 mpox cases, of which 8/11 cases of mpox-HIV co-infection of coinfected patients, and 94.90% (112/118) of mpox patients had skin lesions, of which 90.90% (10/11) were cases of mpox-HIV co-infection. There has also been a gradual increase in cases of severe and critical forms of mpox-HIV co-infection over time following late diagnosis. Conclusion: these results highlight the need for systematic HIV screening in all cases of mpox to exclude any case of mpox-HIV coinfection for holistic management of both diseases. Mpox can now be considered as one of the opportunistic infections of HIV. Preventive measures, including awareness and education of mpox patients, especially on mpox-HIV coinfection, are essential to reduce the number of mpox deaths in the MpoxTC of the Kokolo Health District.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.